You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 9, September 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Macular Degeneration
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

COMMENTS AND OPINIONS

Necessity of Paracentesis Before or After Intravitreal Injection of Bevacizumab

Wei-Cheng Huang, MD; Jane-Ming Lin, MD; Chun-Chi Chiang, MD; Yi-Yu Tsai, MD, PhD

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the study by Bashshur and colleagues,1 0.1 mL of bevacizumab was injected intravitreally; paracentesis was performed only if intraocular pressure (IOP) was greater than 25 mm Hg or the optic nerve head was not adequately perfused 20 minutes after injection. They did not mention how many patients needed paracentesis. I would like to add some comments on the subject.

There are 3 articles2-4 that discuss IOP changes following intravitreal bevacizumab and the necessity of paracentesis; however, the lack of consistency among their conclusions is controversial. Hollands et al3 suggest that clinicians should check IOP after injection or perform a preinjection paracentesis. In a study by Bakri et al,2 no patients required paracentesis, but a few patients required IOP-lowering drops. Falkenstein et al4 reported that paracentesis is unnecessary. These studies, however, used only 0.05 mL of bevacizumab; . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED LETTER

Necessity of Paracentesis Before or After Intravitreal Injection of Bevacizumab—Reply
Ziad F. Bashshur
Arch Ophthalmol. 2008;126(9):1315.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Ziad F. Bashshur, Alexandre Schakal, Rola N. Hamam, Christelle P. El Haibi, Rola F. Jaafar, and Baha’ N. Noureddin
Arch Ophthalmol. 2007;125(10):1357-1361.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.